Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services Screening reduces mortality from breast, cervical, and colorectal cancers. The Guide to Community Preventive Services previously conducted systematic reviews on the effectiveness of 11 interventions to increase screening for these cancers. This article presents results of updated systematic reviews for nine (...) in the reviews.Recommendations were added for one-on-one education to increase screening with fecal occult blood testing (FOBT) and group education to increase mammography screening. Strength of evidence for client reminder interventions to increase FOBT screening was upgraded from sufficient to strong. Previous findings and recommendations for reducing out-of-pocket costs (breastcancerscreening); provider assessment and feedback (breast, cervical, and FOBT screening); one-on-one education and client reminders (breast
(ductal carcinoma in situ and localized disease) and late-stage breastcancer (regional and distant disease) among women 40 years of age or older.The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breastcancer that are detected each year, from 112 to 234 cases per 100,000 women--an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased (...) Effect of three decades of screening mammography on breast-cancer incidence. To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breastcancer
Overdiagnosis of invasive breastcancer due to mammography screening: results from the norwegian screening program. Precise quantification of overdiagnosis of breastcancer (defined as the percentage of cases of cancer that would not have become clinically apparent in a woman's lifetime without screening) due to mammography screening has been hampered by lack of valid comparison groups that identify incidence trends attributable to screening versus those due to temporal trends in incidence.To (...) estimate the percentage of overdiagnosis of breastcancer attributable to mammography screening.Comparison of invasive breastcancer incidence with and without screening.A nationwide mammography screening program in Norway (inviting women aged 50 to 69 years), gradually implemented from 1996 to 2005.The Norwegian female population.Concomitant incidence of invasive breastcancer from 1996 to 2005 in counties where the screening program was implemented compared with that in counties where the program
, randomized controlled trials, or economic evaluations were identified. OVERALL SUMMARY OF FINDINGS Seven non-randomized studies 1-7 suggested the following regarding the clinical effectiveness of 3D ultrasound for screening and diagnosis of breastcancer: 3D ultrasound may serve as a useful tool in distinguishing between benign and malignantbreasttumors 1,5,6,7 of handheld ultrasound-detected cancers, only 57.1- 78.6% were also identified with 3D automated breast ultrasound 2 automated 3D ultrasound (...) to differentiate between benign and malignant solid breasttumors. RESULTS: The accuracy of the MLP model for classifying malignancy was 84.6%, the sensitivity was 90.3%, the specificity was 79.4%, the positive predictive value was 80.0% and the negative 3D Ultrasound for Screening and Diagnosis of BreastCancer 6 predictive value was 90.0%. When the neural network was used to combine the three 3D power Doppler indices, the area under the receiver-operating characteristics curve was 0.89. CONCLUSIONS: 3D power
Understanding recent trends in incidence of invasive breastcancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. To quantify the separate contributions of menopausal hormone treatment and mammography screening activities on trends in incidence of invasive breastcancer between 1987 and 2008.Population study using aggregated data analysed by an extended age-period-cohort model.Norway. Population Norwegian women aged 30-90 between (...) 1987 and 2008, including 50,102 newly diagnosed cases of invasive breastcancer. Main outcomes measures Attributable proportions of mammography screening and hormone treatment to recent incidence of invasive breastcancer, and the remaining variation in incidence after adjustment for mammography screening and hormone treatment.The incidence of invasive breastcancer in Norway increased steadily until 2002, levelled off, and then declined from 2006. All non-linear changes in incidence were explained
cancer.From April 2004-February 2006, 2809 women at 21 sites with elevated cancer risk and dense breasts consented to 3 annual independent screens with mammography and ultrasound in randomized order. After 3 rounds of both screenings, 612 of 703 women who chose to undergo an MRI had complete data. The reference standard was defined as a combination of pathology (biopsy results that showed in situ or infiltrating ductal carcinoma or infiltrating lobular carcinoma in the breast or axillary lymph nodes (...) Detection of breastcancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breastcancer risk. Annual ultrasound screening may detect small, node-negative breastcancers that are not seen on mammography. Magnetic resonance imaging (MRI) may reveal additional breastcancers missed by both mammography and ultrasound screening.To determine supplemental cancer detection yield of ultrasound and MRI in women at elevated risk for breast
over precisely which screening services should be provided and to whom, these methods are frequently used in contemporary practice. 2–4 Outcomes of screening for breastcancer such as tumour detection and mortality must be put into context of the harms and costs of false - positive results, overdiagnosis and overtreatment. Consideration of benefi ts, harms and costs is complicated by variations in risk factors and in the types and stages of cancer. Any positive result from screening has emo- tional (...) Care (2001). 5,6 The absence of current Canadian recommendations, the recent contro- versy over the best way to screen for breastcancer among women at average risk of the disease, 7,8 the availability of new technologies such as magnetic resonance imaging (MRI) and a recent review of the evidence 9 were the basis for selecting this topic for an update by the revitalized Canadian Task Force on Preventive Health Care. Recommendations are presented for the use of mammography, MRI, breast self
Recommendations on screening for breastcancer in average-risk women aged 40-74 years 22106103 2012 01 19 2018 11 13 1488-2329 183 17 2011 11 22 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Recommendations on screening for breastcancer in average-risk women aged 40-74 years. 1991-2001 10.1503/cmaj.110334 Tonelli Marcello M Connor Gorber Sarah S Joffres Michel M Dickinson James J Singh Harminder H Lewin Gabriela G Birtwhistle Richard R (...) Neoplasms diagnosis mortality Canada Female Humans Magnetic Resonance Imaging Mammography Mass Screening Middle Aged Predictive Value of Tests Risk Factors Tonelli Marcello M Birtwhistle Richard R Bacchus Maria M Bell Neil N Brauer Paula P Dickinson James J Joffres Michel M Lewin Gabriela G Lindsay Patrice P Parkin Patricia P Pottie Kevin K Shaw Elizabeth E Singh Harminder H Fortin Martin M 2011 11 23 6 0 2011 11 23 6 0 2012 1 20 6 0 ppublish 22106103 183/17/1991 10.1503/cmaj.110334 PMC3225421 Ann
Possible net harms of breastcancerscreening: updated modelling of Forrest report. To assess the claim in a Cochrane review that mammographic breastcancerscreening could be doing more harm than good by updating the analysis in the Forrest report, which led to screening in the United Kingdom.Development of a life table model, which replicated Forrest's results before updating and extending them with data from relevant systematic reviews, trials, and other models based on purposive literature (...) searches.Women aged 50 and over invited for breastcancer screening.Quality adjusted life years (QALYs), combining life years gained from screening with losses of quality of life from false positive diagnoses and surgery.Inclusion of the effects of harms reduced the updated estimate of net cumulative QALYs gained after 20 years from 3301 to 1536 or by more than half. The best estimates from the Cochrane review generated negative QALYs for the first seven years of screening, 70 QALYs after 10 years, and 834
Effect of mammography screening on surgical treatment for breastcancer in Norway: comparative analysis of cancer registry data. To determine the effect of mammography screening on surgical treatment for breast cancer.Comparative analysis of data from Norwegian cancer registry.Mammography screening, Norway (screening of women aged 50-69 was introduced sequentially from 1996 to 2004).35,408 women aged 40-79 with invasive breastcancer or ductal carcinoma in situ treated surgically from 1993 (...) younger age group.Mammography screening in Norway was associated with a noticeable increase in rates for breastcancer surgery in women aged 50-69 (the age group invited to screening) and also an increase in mastectomy rates. Although over-diagnosis is likely to have caused the initial increase in mastectomy rates and the overall increase in surgery rates in the age group screened, the more recent decline in mastectomy rates has affected all age groups and is likely to have resulted from changes
Breastcancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. To compare trends in breastcancer mortality within three pairs of neighbouring European countries in relation to implementation of screening.Retrospective trend analysis.Three country pairs (Northern Ireland (United Kingdom) v Republic of Ireland, the Netherlands v Belgium and Flanders (Belgian region south of the Netherlands (...) ), and Sweden v Norway).WHO mortality database on cause of death and data sources on mammography screening, cancer treatment, and risk factors for breastcancer mortality.Changes in breastcancer mortality calculated from linear regressions of log transformed, age adjusted death rates. Joinpoint analysis was used to identify the year when trends in mortality for all ages began to change.From 1989 to 2006, deaths from breastcancer decreased by 29% in Northern Ireland and by 26% in the Republic of Ireland
Full-field digital mammography for breastcancerscreening Full-field digital mammography for breastcancerscreening Full-field digital mammography for breastcancerscreening Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Full-field digital mammography for breastcancerscreening. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' objectives Full (...) -field digital mammography (FFDM) is an alternative to conventional screen-film mammography (SFM), the standard of care for detecting breastcancer. With digital mammography, images of the breast are acquired, displayed, transferred, and stored as digital data for viewing on a computer monitor (soft-copy reading) or for printing and viewing with a light box (hard-copy reading). In contrast to SFM, FFDM simplifies image interpretation because image acquisition, image processing, image review, and data
Accuracy and outcomes of screening mammography in women with a personal history of early-stage breastcancer. Women with a personal history of breastcancer (PHBC) are at risk of developing another breastcancer and are recommended for screening mammography. Few high-quality data exist on screening performance in PHBC women.To examine the accuracy and outcomes of mammography screening in PHBC women relative to screening of similar women without PHBC.Cohort of PHBC women, mammogram matched (...) to non-PHBC women, screened through facilities (1996-2007) affiliated with the BreastCancer Surveillance Consortium.There were 58,870 screening mammograms in 19,078 women with a history of early-stage (in situ or stage I-II invasive) breastcancer and 58,870 matched (breast density, age group, mammography year, and registry) screening mammograms in 55,315 non-PHBC women.Mammography accuracy based on final assessment, cancer detection rate, interval cancer rate, and stage at diagnosis.Within 1 year
Background Breastcancer is a disease of aging with a four-fold higher incidence in women 50 to 69 years of age (500 per 100,000 women) compared to women 40 to 49 years of age (140 per 100,000 women). The estimated number of new breastcancer diagnoses in Ontario women 40 to 49 year of age is approximately 1,400 per year. There are approximately 1.02 million women in this age group in Ontario at present. The MAS review assessed the effectiveness of screening (film) mammography in women 40 to 49 years (...) Screening Mammography for Women Aged 40 to 49 Years at Average Risk for BreastCancer 1 OHTAC Recommendation Screening Mammography for Women Aged 40 to 49 Years at Average Risk for BreastCancer Updated January 2011 This recommendation summary has been prepared by the Medical Advisory Secretariat of the Ministry of Health and Long Term Care on behalf of the Ontario Health Technology Advisory Committee. Presented to the Ontario Health Technology Advisory Committee in November, 2010 Issue
Effectiveness of mammography screening in reducing breastcancer mortality in women aged 39-49 years: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Organizational change: a way to increase colon, breast and cervical cancerscreening in primary care practices Organizational change: a way to increase colon, breast and cervical cancerscreening in primary care practices Organizational change: a way to increase colon, breast and cervical cancerscreening in primary care practices Arroyave AM, Penaranda EK, Lewis CL CRD summary Organisational change interventions that circumvented the physician were most effective in increasing cancerscreening (...) published in English between January 1990 and July 2010. Search terms were reported. References of relevant studies were handsearched for further studies. Study selection Eligible randomised controlled trials (RCTs) that reported the impact of organisational change interventions implemented by practice staff on colorectal, breast or cervical cancerscreening rates. Eligible outcomes were test completion of flexible sigmoidoscopy, colonoscopy, faecal occult blood test, mammography, clinical breast